Myricetin
Cell studies, rodent studies, and not one human trial: the shortest honest file in the library.
D
Evidence grade
D
Worth it
$12-22/month
Typical cost
DoseProducts typically provide 100 to 300 mg/day. No dose is established for any purpose, because no effect is established for any purpose. Dietary intake is a few milligrams a day from tea, berries, and wine.
BasisSome records in this library grade compounds whose evidence is mixed, thin, or disappointing.
Myricetin is a flavonoid found in berries, tea, and red wine, sold as an antioxidant and metabolic supplement. We grade Myricetin D on evidence and D for worth-it at about $12-22 per month.
What it does
Myricetin is a flavonoid found in berries, tea, and red wine, sold as an antioxidant and metabolic supplement. Its presence in this library comes from list frequency in the longevity market, and its record is correspondingly brief.
What the research says
No human trial of isolated myricetin exists for any outcome
Evidence: weak. The file, in full: pharmacokinetic studies showing myricetin is absorbed poorly and metabolized quickly; animal studies in diabetes, neurodegeneration, and cancer models; cell studies. Nothing else. The queue that commissioned this record anticipated exactly this finding, noting that thin human data is itself a gradeable answer. This is it.
Dietary myricetin rides inside flavonoid epidemiology that cannot isolate it
Evidence: weak. Tea, berries, and red wine contain myricetin among dozens of flavonoids. Cohort studies linking flavonoid-rich diets to better outcomes say nothing separable about this molecule, and nothing about the isolated supplement at any dose.
Some records in this library grade compounds whose evidence is mixed, thin, or disappointing. Myricetin's is absent. It is sold on cell and rodent studies alone, at doses humans absorb poorly, for claims no human study has ever tested. D is the grade for a marketed ingredient with a preclinical-only file, and this record stands as the library's clearest statement that being natural, studied in animals, and listed in protocols are not evidence.
Is it worth it?
Evidence (D) sits far below the leaderboard floor, and the derived value at this price is also D. About $17 a month at common doses. Derived from the October 2026 worth-it model.
Typical cost
$12-22/month
Common form, not a brand recommendation
Dosage context established
Products typically provide 100 to 300 mg/day. No dose is established for any purpose, because no effect is established for any purpose. Dietary intake is a few milligrams a day from tea, berries, and wine.
Worth-it leaderboard
Myricetin sits outside the worth-it top 20.
Myricetin sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
No human safety data of consequence exist either; the absence of harm reports reflects the absence of study and of widespread use, not a demonstrated profile. Poor oral bioavailability likely limits both effect and risk. Standard cautions for untested compounds apply in pregnancy and alongside medication.
Longevity Lab Report
Myricetin news. Graded when it happens.
The grade on this page stays free. The email carries the news on myricetin: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from a complete search of the human literature: no randomized trial of isolated myricetin exists. The record is deliberately short, because the evidence is.
- 2026-10-23|Not listed under any goal: no graded human benefit exists to map.
The week's longevity and biohacking news.
This grade for Myricetin rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.